Company Overview
Snapshot
Founded in August 2023, Watershed AC operates with 1–10 employees. The company has secured one funding round. In May 2024, Watershed AC received a grant from the Israel Innovation Authority.
Business overview
Watershed AC is an Israel-based biotechnology and sustainable aquaculture company that develops advanced gene-editing technologies, such as CRISPR. The company focuses on improving crustacean traits like growth rate, disease resistance, and environmental adaptation, serving the aquaculture and agtech sectors.
Strategic signal
In October 2024, Watershed AC, in collaboration with Evogene and Ben-Gurion University, received approval for a second-year grant from the Israel Innovation Authority to advance their CRISPR technology for crustaceans. This signals strong validation of their gene-editing approach and its potential to scale for industrial use, addressing critical needs in sustainable aquaculture by enhancing species like giant freshwater prawn, white leg shrimp, and red swamp crayfish.
Log in to access full profile ›Company Intelligence Q&A
- What is Watershed AC's primary focus?
- Watershed AC focuses on developing advanced gene-editing technologies, including CRISPR, to improve crustacean traits such as growth rate, disease resistance, and environmental adaptation for sustainable aquaculture.
- When was Watershed AC founded?
- Watershed AC was founded in August 2023.
- Has Watershed AC received any grants?
- Yes, in May 2024, Watershed AC received a grant from the Israel Innovation Authority.
- What significant collaboration is Watershed AC involved in?
- In October 2024, Watershed AC, Evogene, and Ben-Gurion University received approval for a second-year grant from the Israel Innovation Authority to continue their collaboration on developing CRISPR technology for crustaceans.
- What is the goal of the collaboration with Evogene and Ben-Gurion University?
- The collaboration aims to address limitations in gene editing for non-model organisms, focusing on improving traits like growth rate and disease resistance in crustaceans, with plans to scale the technology for industrial use.